Key Drivers
- Strong margins
- Manageable leverage
- Tightening liquidity
AIAI Summary
ATR should now be viewed less as a defensive compounder and more as a “show-me” growth story: revenue momentum in Pharma is real, but the stock's next move depends on whether that growth can finally translate into margin expansion and stronger free cash flow rather than just sales growth.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong margins
- •Manageable leverage
- •Tightening liquidity
ATR remains financially stable and profitable with solid margins, cash generation, and manageable leverage, but valuation is rich and liquidity has tightened as cash fell below debt.
Price Behavior
Key Price Behavior Insights:
- •Range-bound trade
- •Lower highs
- •Support holding
Last month, ATR stayed range-bound as support held near $128.5 but lower highs and repeated rejections at $135.5-$137.3 show weakening momentum unless the stock breaks back above resistance.
Sharp mid-period rally from $127.2 to $137.3 before momentum faded
Sentiment & News
Key News Insights:
- •Q2 Beat
- •Pharma Strength
- •Leadership Change
AptarGroup's latest news flow is constructive, driven by repeated Q2 2026 beats, broad-based sales growth, Pharma strength, ongoing innovation, and supportive investor sentiment despite some margin pressure.
Overall, the news is mildly positive for AptarGroup, supporting the stock's growth narrative while keeping margin and transition risks in focus
Similar Companies in Healthcare
Other companies in the same sector with AI ratings